Recent Development in Thrombin Receptor Antagonist as Novel Antithrombotic Agent ()
ABSTRACT
Significant progress was achieved in the search of a thrombin receptor antagonist as a novel antithrombotic treatment since the thrombin receptor (protease-activated receptor-1, PAR-1) was cloned 20 years ago. Previous works have shown that it is possible to develop potent thrombin receptor antagonists to compete effectively with the receptor’s internal “tethered” ligand to block platelet activation. Vorapaxar (SCH 530348) from Schering-Plough (now Merck) and atopaxar (E5555) from Eisai have been advanced to human clinical trials. Recently, the pivotal phase III clinical trial results for vorapaxar were published. In this article we review these results plus the phase II results from atopaxar. Several newly described thrombin receptor antagonists from the literature will also be discussed. The phase III results from vorapaxar demonstrated that a thrombin receptor antagonist can achieve efficacy in addition to current standard- of-care in treating atherothrombotic patients, especially those with previous myocardial infarction (MI). However, the increased moderate and severe bleeding, especially intracranial bleeding, point to the limitations of current thrombin receptor antagonists. Future thrombin receptor antagonists that can improve on the efficacy and bleeding profile of current ones should have a promising place in meeting the unmet medical need in treating atherothrombotic patients using current standard therapy.
Share and Cite:
H. Cui, W. Tan, J. Shi and Y. Xia, "Recent Development in Thrombin Receptor Antagonist as Novel Antithrombotic Agent,"
Open Journal of Medicinal Chemistry, Vol. 2 No. 4, 2012, pp. 112-118. doi:
10.4236/ojmc.2012.24014.
Cited by
[1]
|
缺血性脑卒中的治疗研究进展
|
|
中国新药杂志,
2016 |
|
|
[2]
|
Protease-Activated Receptor 1 (PAR-1) Antagonists as Potential Treatment for Acute Coronary Syndrome
|
|
ACS Medicinal Chemistry Letters,
2016 |
|
|
[3]
|
6, 7-二甲氧基-2-(1-吡咯烷)-4-[5-(1-吡咯烷) 戊烷基] 氨基喹唑啉的合成
|
|
化学试剂,
2015 |
|
|
[4]
|
N′-(7-氟吡咯并 [1, 2-a] 喹喔啉)-吡嗪-2-甲酰肼盐酸盐的合成
|
|
化学试剂,
2014 |
|
|
[5]
|
凝血酶受体拮抗剂在抗血栓方面的研究进展
|
|
中国药物化学杂志,
2014 |
|
|
[6]
|
2-(1E, 3E)-5-氧代-5-(4-(2-吡啶) 哌嗪)-1, 3-戊二烯苯甲氰的合成及生物活性
|
|
化学试剂,
2014 |
|
|
[7]
|
聚乙二醇双咪唑型离子液体促进 RhCl3 催化烯烃硅氢加成反应的研究
|
|
化学试剂,
2014 |
|
|